Driving change to defeat serious chronic disease
Novo Nordisk (novonordisk-us.com) scores 84 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, in the 92nd percentile of 19734 Healthcare brands.
Novo Nordisk is a Danish pharmaceutical company founded in 1923 and headquartered in Bagsværd, Denmark. It develops treatments for diabetes, obesity, rare bleeding disorders, and growth hormone-related disorders, including once-weekly basal insulin therapies. Owned by Novo Holdings and led by CEO Lars Fruergaard Jørgensen, the company serves patients and healthcare providers in the U.S. and globally, positioning itself as a leader in medical innovation for serious chronic diseases.
| Brand Name | Novo Nordisk |
|---|---|
| Domain | novonordisk-us.com |
| Industry | Healthcare |
| Founded | 1923 |
| Headquarters | Bagsværd |
| Parent Company / Owner | Novo Holdings |
| CEO | Lars Fruergaard Jørgensen |
| Main Competitors | Eli Lilly (78/100), Sanofi (90/100), Pfizer (89/100), AstraZeneca (82/100), Roche (81/100), Merck (81/100), Boehringer Ingelheim (76/100), Amgen (90/100) |
Moz Domain Authority 59/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #238,405 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Novo Nordisk has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Learn all about Novo Nordisk in the U.S. and how we're helping to defeat diabetes, rare bleeding disorders, growth hormone-related disorders, and obesity." (Meta description: 23 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: Microdata (Schema.org), og:title, og:description, og:image, og:type, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on Instagram, X (Twitter), LinkedIn, YouTube; no detected presence on Facebook, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Novo Nordisk?", Claude could identify the brand as of September 2026. Novo Nordisk is a Danish multinational pharmaceutical company that has been a leader in diabetes care for nearly a century, producing insulin and other treatments for diabetes, obesity, and related chronic conditions. Best known for Pioneering insulin production and more recently for GLP-1 drugs like Ozempic and Wegovy used for diabetes management and weight loss.
When asked "Best brands similar to Novo Nordisk?", Claude would recommend Novo Nordisk as of September 2026. It's one of the biggest and most influential names in diabetes and obesity treatment, so it would naturally come up alongside companies like Eli Lilly when discussing leaders in that space.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Novo Nordisk's main competitors in Healthcare: Eli Lilly (78/100), Sanofi (90/100), Pfizer (89/100), AstraZeneca (82/100), Roche (81/100).
Sources: Brand Analyzer scan
Novo Nordisk offers pharmaceutical treatments for diabetes, including once-weekly basal insulin therapies, as well as treatments for obesity, rare bleeding disorders, and growth hormone-related disorders. The company also provides patient support resources alongside its medical products, focusing on science-driven, innovative therapies for these serious chronic health conditions.
Sources: Novo Nordisk official site
Novo Nordisk is a Danish pharmaceutical company founded in 1923 and headquartered in Bagsværd, Denmark. It is owned by Novo Holdings and led by CEO Lars Fruergaard Jørgensen. The company focuses on developing treatments for serious chronic diseases, including diabetes, obesity, rare bleeding disorders, and growth hormone-related disorders, and operates globally, including a significant presence in the United States.
Sources: Novo Nordisk official site
Novo Nordisk has moderate AI-search visibility, scoring 57/100 on Brand Analyzer's AI visibility composite (visibility 70, trust 33, recommendation 62). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Novo Nordisk official site
Novo Nordisk was founded in 1923. Novo Nordisk operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Novo Nordisk is headquartered in Bagsværd. Novo Nordisk operates in the Healthcare category.
Sources: Wikidata
Novo Nordisk researches, develops, and manufactures pharmaceutical treatments for chronic diseases. Its work centers on diabetes care, obesity management, rare bleeding disorders, and growth hormone-related disorders. The company develops innovative therapies, such as once-weekly basal insulin, and provides patient support programs alongside its medical products, aiming to help patients manage and ultimately defeat these serious health conditions.
Sources: Novo Nordisk official site
Novo Nordisk scores 62/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Novo Nordisk official site
Novo Nordisk is known for its leadership in diabetes care and insulin production, as well as its development of innovative treatments like once-weekly basal insulin. The company is also recognized for its work in obesity treatment, rare bleeding disorders, and growth hormone-related disorders, positioning itself as a global healthcare innovator dedicated to combating serious chronic diseases through science-driven research.
Sources: Novo Nordisk official site
Novo Nordisk can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Novo Nordisk official site
Novo Nordisk's products and services are used by patients with diabetes, obesity, rare bleeding disorders, and growth hormone-related disorders, as well as the healthcare providers who treat them. Its primary focus in this context is the U.S. market, where it provides treatments and patient support tailored to these specific chronic disease populations.
Sources: Novo Nordisk official site
Novo Nordisk is owned by or part of Novo Holdings. Novo Nordisk operates in the Healthcare category.
Sources: Wikidata
Novo Nordisk is recognized for its innovative, science-driven treatments for chronic diseases, particularly its breakthroughs in diabetes care such as once-weekly basal insulin. Its long history since 1923 and focus on patient-centered care across diabetes, obesity, rare bleeding disorders, and growth hormone-related conditions have contributed to its prominence as a global healthcare leader in these therapeutic areas.
Sources: Novo Nordisk official site
Novo Nordisk scores 57/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Novo Nordisk has a limited AI-visibility profile at 57/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (70/100) and its weakest is trust (33/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #238,405 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Novo Nordisk from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Novo Nordisk: Novarad (84/100), Nookal (84/100), NovoPath (84/100), National University of Health Sciences (84/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.